论文部分内容阅读
目的观察卡维地洛对慢性心力衰竭(CHF)患者血浆脑钠肽(BNP)及左心室收缩功能的变化。方法CHF患者87例,分卡维地洛治疗组(B组)44例和常规治疗组(A组)43例。随访6个月,评估两组治疗前、治疗后1个月、3个月及6个月患者心功能指标和血浆BNP浓度。结果治疗后1个月两组血浆BNP水平较治疗前下降(P<0.05),3个月时下降更明显。3个月组间比较有显著性差异(P<0.05);两组患者治疗1个月后左心室舒张末内径(LVEDD)、左心室收缩末内径(LVESD)及左心室射血分数(LVEF)与治疗前比较均无统计学差异(P>0.05);6个月时的上述指标与治疗前比较均有显著性差异(P<0.05)。两组患者血浆BNP水平与同期测定的左心室舒张末内径呈正相关(r=0.51,P<0.01),与LVEF呈负相关(r=-0.43,P<0.01)。结论卡维地洛能有效地改善CHF患者的心功能;CHF患者BNP水平的变化早于心脏超声指标的变化:血浆BNP水平可以作为治疗心力衰竭的一个可靠观察指标。
Objective To observe the changes of plasma brain natriuretic peptide (BNP) and left ventricular systolic function in patients with chronic heart failure (CHF) treated with carvedilol. Methods A total of 87 patients with CHF, 44 patients with carvedilol treatment (group B) and 43 patients with conventional therapy (group A). The patients were followed up for 6 months to evaluate the cardiac function and plasma BNP levels before treatment, 1 month, 3 months and 6 months after treatment. Results At 1 month after treatment, plasma BNP levels in both groups decreased compared with those before treatment (P <0.05), and were more obvious at 3 months. (LVEDD), left ventricular end-systolic diameter (LVESD) and left ventricular ejection fraction (LVEF) in the two groups after treatment for one month There was no significant difference between before treatment and before treatment (P> 0.05). The above indexes at 6 months were significantly different from those before treatment (P <0.05). Plasma BNP levels were positively correlated with left ventricular end-diastolic diameter (r = 0.51, P <0.01) in the two groups and negatively correlated with LVEF (r = -0.43, P <0.01). Conclusions Carvedilol can effectively improve the cardiac function in patients with CHF. The changes of BNP in CHF patients before the change of cardiac ultrasound indexes: the plasma BNP level can be used as a reliable observation index in the treatment of heart failure.